| Document |
Document Title |
|
JP5745841B2 |
The invention relates to a process for the optical resolution of a dibenzo[b,d]azepinone derivative of formula II, wherein R1 is hydrogen or halogen and R2 is either C1-4-alkyl optionally substituted with C3-7-cycloalkyl or benzyl which ...
|
|
JP2015120692A |
To provide: novel organic electroluminescent compounds which exhibit good electroluminescence efficiency and excellent life properties of material; and organic electroluminescent devices using the same as electroluminescent material.The ...
|
|
JP2015517977A |
A process for the conversion of adipic acid to caprolactam is disclosed, which employs a proprietary solvent in the presence of a particular heterogeneous catalyst and a chemical catalytic reaction in which the adipic acid substrate reac...
|
|
JP5732159B2 |
Synthesis of dihydro-1H-benzo[d]azepine (I) involves subjecting 7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine-2,4-dione (VII) to reduction reaction in presence of lithium triethylborohydride in an organic solvent. Synthesis of dihydr...
|
|
JP5727649B2 |
This invention relates to five specific N-hydroxybenzamide compounds for the inhibition of histone deacetylase: N-hydroxy-4-(5-(p-tolyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)
benzamide; N-hydroxy-4-(5-(3-methoxyphenyl)-2,5-diazabicyclo[2.2...
|
|
JP5727376B2 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells comprising the same. Specifically, the organic electroluminescent compounds according to the invention are characteri...
|
|
JP5727937B2 |
The disclosure describes method of synthesis of substituted benzazepine derivatives. Preferred methods according to the disclosure allow for large-scale preparation of benzazepine compounds having low levels of metal impurities. In some ...
|
|
JP2015098485A |
To provide novel pharmaceuticals for hypertensive vascular diseases.The present invention provides novel dual-acting compounds and pharmaceutical combinations of angiotensin receptor antagonists and neutral endopeptidase inhibitors. More...
|
|
JP5723522B2 |
Provided are a novel organic electroluminescent compound and an organic electroluminescent device using the same as an electroluminescent material. The disclosed organic electroluminescent compound is represented by Chemical Formula 1: w...
|
|
JP5717645B2 |
An object of the present invention is to provide a novel benzazepine compound or a salt thereof, which has excellent vasopressin antagonistic activity. The benzazepine compound or a salt thereof of the present invention is represented by...
|
|
JP5710491B2 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells including the same. The organic electroluminescent compound is represented by Chemical Formula 1: wherein L is a subs...
|
|
JP2015083600A |
To provide a simple method of removing a fluorescent by-product contained in the resulting product mixture from a product mixture as perfectly as possible in a well-known method for producing an N-vinylamide.A crude N-vinylamide is extra...
|
|
JP2015078237A |
To provide a substituted hydroxamic acid and use thereof.Provided is a compound of formula (I) that is useful as an inhibitor of HDAC6, where R, R, G, m, n, p, and q have the meaning as described herein. Also provided are pharmaceutical ...
|
|
JP5697635B2 |
|
|
JP5689195B2 |
The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is r...
|
|
JP5673169B2 |
A quaternary ammonium salt represented by formula (5) (wherein R 1 represents an alkyl group having 1 to 4 carbon atoms, R 2 represents an alkyl group having 1 to 10 carbon atoms, R 3 represents an alkyl group having 1 to 10 carbon atoms...
|
|
JP5670406B2 |
Preparing (P1) ivabradine (I) involves reductive amination reaction of 4-(7,8-dimethoxy-2-oxo-1,2,4,5-tetrahydro-benzo[d]azepin-3-y
l)-butyraldehyde (V) with ((S)-3,4-dimethoxy-bicyclo[4.2.0]octa-1(6),2,4-trien-7-ylmet
hyl)-methyl-amine ...
|
|
JP5667593B2 |
The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disord...
|
|
JP2015028016A |
To provide an ionic liquid composition and a manufacturing method of an ionic liquid.The provided ionic liquid includes a cation expressed by the formula (I). A manufacturing method of an ionic liquid including a step of executing at lea...
|
|
JP5663964B2 |
To provide a method for producing an N-vinylamide which attains extremely high conversion and selectivity in the production of an N-vinylamide by dealcoholation reaction of N-(α-alkoxyalkyl)amide, and a catalyst used in the method.Accor...
|
|
JP2015501788A |
The present invention is useful in methods of treating and alleviating heart, brain, kidney, immune, and reproductive system diseases and disorders resulting from ischemia or post-ischemia reperfusion and any downstream complications ass...
|
|
JP5653043B2 |
The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is r...
|
|
JP5650781B2 |
Pyridine-piperazine-phenyl derivatives (I) or their enantiomers, diastereomers or salts, preferably salts with organic or inorganic acid or base, are new. Pyridin-piperazin-phenyl derivative (I) of formula (R 5>-A-R 4>-B 1>-R 3>-A-D-Y 1>...
|
|
JP5643103B2 |
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteri...
|
|
JP2014234356A |
To provide an efficient and inexpensive synthesis method of a fluorine-containing organic compound by an olefin aminofluorination reaction using a nucleophilic fluorinating agent being a super-valent iodine reagent.A nucleophilic portion...
|
|
JP5640017B2 |
Methods for the preparation of Ivabradine sulfate and form I crystal thereof. In particular, the Ivabradine sulfate and the preparation methods thereof, and the stable form I crystal of Ivabradine sulfate and the preparation methods ther...
|
|
JP5634660B2 |
A process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide
(1) by ring opening of 11a,10b-dihydro-6H-dibenz/b,f/oxireno[d]azepine-6-carboxamid
e (5), characterised in that the ring opening is carried o...
|
|
JP5632279B2 |
The present invention provides Crystalline ivabradine oxalate, optionally in a form characterized by at least one of the following: a) power X-ray diffraction peaks at about 2.04, 2.13, 4.26, 7.06, 8.02, 8.53, 9.32, 10.91, 13.63, 15.07, ...
|
|
JP5612482B2 |
The present invention provides a method for treating a patient having cancer comprising administering to the patient a therapeutically effective amount of compound (1), or a pharmaceutically acceptable salt thereof, having the formula: T...
|
|
JP5603849B2 |
The invention relates to benzofuran or benzothiophene derivatives, to processes for preparing them, to pharmaceutical compositions comprising them, and to the method of use thereof in the treatment of pathological syndromes of the cardio...
|
|
JP5602116B2 |
The present relation relates to 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -3-benzazepine or a pharmaceutically acceptable salt, solvate, or hydrate thereof for the treatment of a disorder of the central nervous system selected from: depre...
|
|
JP2014189462A |
To provide a manufacturing method of a crystal that can selectively manufacture a metastable crystal form.A manufacturing method of a crystal is a manufacturing method of a crystal of a substance having crystal polymorphism, wherein a cr...
|
|
JP5597689B2 |
A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.
|
|
JP5593095B2 |
|
|
JP2014159375A |
To provide a compound having activities of inhibiting monoamine reuptake and to provide a prophylactic or therapeutic agent for depression, anxiety, attention deficit and hyperactivity disorder, climacteric disturbance, pain, abdominal p...
|
|
JP2014156490A |
To provide crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride.The present invention is directed to crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, compositions con...
|
|
JP5580075B2 |
|
|
JP5580915B2 |
Preparing 2-[3-[(3,4-dimethoxy-7-bicyclo[4.2.0]octa-1(6),2,4-trienyl)m
ethyl-methyl-amino]propyl]-6,7-dimethoxy-1,4-dihydroisoquino
lin-3-one (I) comprises subjecting 2-[2-[2-[3-[(3,4-dimethoxy-7-bicyclo[4.2.0]octa-1(6),2,4-tri
enyl)meth...
|
|
JP5574327B2 |
|
|
JP5572839B2 |
|
|
JP2014141441A |
To provide a medicine excellent in safety which has an activity of suppressing fibrosis accompanying overproduction and accumulation of an extracellular matrix component by alleviating the side effect about phototoxicity or a digestive s...
|
|
JP5566282B2 |
The aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepine derivative compounds of the present invention are represented by formulae (I) (A-E) having the following structure where the carbon atom designated * is in the R or S confi...
|
|
JP5563600B2 |
Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.
|
|
JPWO2012124744A1 |
Provided is a compound represented by the following general formula (I) having an excellent monoacylglycerol acyltransferase 2 inhibitory action or a pharmaceutically acceptable salt thereof. [Chemical 1] (I) [In the formula, ring A repr...
|
|
JP2014133771A |
To provide processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity....
|
|
JP2014516929A |
The present invention generally relates to processes for the conversion of glucose to caprolactam employing chemocatalytic oxidation and reduction reactions. The present invention also includes processes for the conversion of glucose to ...
|
|
JP5549592B2 |
|
|
JPWO2012099237A1 |
It comprises an anode 10, a cathode 20, and a light emitting layer 30 that is liquid at room temperature and is interposed between these poles, and the light emitting layer is, for example, the first oxidation and / or the first oxidatio...
|
|
JP5531084B2 |
Synthesis of ivabradine involves subjecting 3-(7,8-dimethoxy-2-oxo-1,2,4,5-tetrahydro-benzo[d]azepin-3-y
l)-propionaldehyde to a reductive amination reaction with ((S)-3,4-dimethoxy-bicyclo[4.2.0]octa-1,2,4-trien-7-ylmethyl
)-methyl-amin...
|
|
JP5529202B2 |
Pyridine-piperazine-phenyl derivatives (I) or their enantiomers, diastereomers or salts, preferably salts with organic or inorganic acid or base, are new. Pyridin-piperazin-phenyl derivative (I) of formula (R 5>-A-R 4>-B 1>-R 3>-A-D-Y 1>...
|
